The clinicopathologic characteristics and tumor immune microenvironment of pulmonary enteric adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pulmonary enteric adenocarcinoma (PEAC) is a rare lung cancer. This study found PEAC tumors are immunologically "cold," suggesting limited benefit from current immunotherapy. Further research into molecular markers is needed for better treatment.
Area Of Science
- Oncology
- Immunology
- Pathology
Background
- Pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of lung adenocarcinoma with limited reporting.
- Effective treatment and prognosis prediction for PEAC require ongoing exploration of molecular markers.
Purpose Of The Study
- To investigate the clinicopathological features of PEAC.
- To analyze the tumor immune microenvironment (TIME) in PEAC patients.
- To evaluate the expression of immune markers like LAG-3 and PD-L1 in PEAC.
Main Methods
- Retrospective enrollment of 10 PEAC patients.
- Analysis of clinicopathological features.
- Immunohistochemical assessment of LAG-3, PD-L1, MMR proteins, CD3, CD8A, CD45RO, and PanCK to characterize TIME.
Main Results
- PEAC predominantly affects middle-aged to elderly males.
- All analyzed patients exhibited microsatellite stability (MSS) with negative PD-L1 and low LAG-3 expression.
- TIME analysis indicated "cold tumors," suggesting potential unresponsiveness to immunotherapy.
Conclusions
- PEAC is a rare variant of lung adenocarcinoma with distinct morphological features.
- PEAC patients in this cohort displayed characteristics of "cold tumors" with low immune cell infiltration and negative PD-L1 expression.
- These findings suggest that PEAC patients may not benefit from current immunotherapies, highlighting the need for novel therapeutic strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...